|
|
|
front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |review |
 |
CARE实验包括576（14%）的女性，她们的平均位于基线的HDL-C为45m/dl，这对于女性来说是最低临界线。Pravastatin可以显著的使复合冠脉事件（冠脉引起死亡，非死亡心肌梗塞，经皮经腔血管成形术[PTCA]，以及冠状动脉分流移植术[CABG]）降低45%，PTCA降低48%；CABG和中风的降低虽然很有价值但在统计上并不重要。
参考文献：
Lewis SJ, Sacks FM, Mitchell
JS, East C, Glasser S, Kell S, Letterer R, Limacher M, Moye LA,
Rouleau JL, Pfeffer MA, Braunwald E,
for the CARE investigators. Effect of pravastatin on cardiovascular
events in women after myocardial infarction: the Cholesterol and
Recurrent Events (CARE) trial. J Am Coll Cardiol 1998;32:140-146
|